DnB Nor, Gezina and Glastad Invest, together with existing investors, InnovationsKapital and Teknoinvest have completed a further $7m funding round for SantoSolve, an Oslo-based biotech company. The investment will be used to support trasition into phase III clinical trial of the company’s promising pain reliever.
Consortium of investors supporting the funding round includes existing and new backers
Vehicle is larger than its predecessor, Xenon Private Equity VI, a €184m fund closed in July 2014
GP intends to boost the company's organic growth and further strengthen its market position
Acquisition of the family-owned company adds to the GP's industrial portfolio